Methods and compositions for inducing protective immunity against filovirus infection

Patent metadata

Field	Value
Publication number	US-11918639-B2
Application number	US-202117450465-A
Country	US
Kind code	B2
Filing date	Oct 11, 2021
Priority date	Sep 3, 2014
Publication date	Mar 5, 2024
Grant date	Mar 5, 2024

Abstract

The present invention provides compositions, vaccines and methods for inducing protective immunity against filovirus infection, particularly protective immunity against infection of one or more subtypes of Ebola viruses and Marburg virus.

First claim

What is claimed is:

1. A vaccine combination comprising
(i) a first composition comprising an immunologically effective amount of an adenovirus vector comprising a nucleic acid encoding an antigenic protein having SEQ ID NO:1, together with a pharmaceutically acceptable carrier; and
(ii) a second composition comprising an immunologically effective amount of an MVA vector comprising a nucleic acid encoding antigenic proteins from four filovirus subtypes having SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:4, and SEQ ID NO:5, together with a pharmaceutically acceptable carrier;

wherein the first composition is a priming composition and the second composition is a boosting composition.

2. The vaccine combination according to claim 1 , wherein the first composition (i) further comprises an adenovirus vector comprising a nucleic acid encoding an antigenic protein of a second filovirus subtype.

3. The vaccine combination according to claim 2 , wherein the first composition (i) further comprises an adenovirus vector comprising a nucleic acid encoding an antigenic protein of a third filovirus subtype.

4. The vaccine combination according to claim 1 , wherein composition (i) further comprises an adenovirus comprising a nucleic acid encoding an antigenic protein with SEQ ID NO:2.

5. The vaccine combination according to claim 4 , wherein composition (i) further comprises an adenovirus comprising a nucleic acid encoding an antigenic protein with SEQ ID NO:3.

6. The vaccine combination according to claim 1 , wherein the adenovirus vectors are rAd26 or rAd35 vectors.

7. The vaccine combination according to claim 1 , wherein the adenovirus vector is administered in an amount of 10 9 to about 10 12 viral particles (vp) to a human subject.

8. The vaccine combination according to claim 1 , wherein the MVA vector is administered in an amount of 1×10 7 TCID50 to 1×10 9 TCID50 to a human subject.

9. The vaccine combination according to claim 1 for use in generating a protective immune response against an Ebola virus.

10. The vaccine combination according to claim 1 for use in the preparation of a pharmaceutical composition or medicament.

Assignees

• Bavarian Nordic As
• Janssen Vaccines & Prevention Bv
• Us Health
• The Us Secretary Department Of Health And Human Service

Inventors

• Volkmann Ariane
• Steigerwald Robin
• Dirmeier Ulrike
• Pau Maria Grazia
• Callendret Benoit Christophe Stephan
• Ward Lucy A

Classifications

• A61K39/12 Primary

  Viral antigens · CPC title

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• A61K2039/5254

  avirulent or attenuated · CPC title

• A61K2039/5256

  expressing foreign proteins · CPC title

• A61K2039/545

  characterised by the dose, timing or administration schedule · CPC title